Kestra Medical Technologies First Quarter 2026 Earnings: Beats Expectations

Kestra Medical Technologies (NASDAQ:KMTS) First Quarter 2026 Results

Key Financial Results

• Revenue: US$19.4m (up 52% from 1Q 2025).
• Net loss: US$25.8m (loss widened by 16% from 1Q 2025).
• US$0.50 loss per share.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kestra Medical Technologies Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 8.4%. Earnings per share (EPS) also surpassed analyst estimates by 45%.

Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 30% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Kestra Medical Technologies you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.